Axsome Therapeutics

About:

Axsome Therapeutics is a biopharmaceutical company that develops therapies for the management and treatment of neurological disorders.

Website: http://axsome.com

Twitter/X: axsome

Description:

Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of pain and other neurological diseases. By focusing on this therapeutic area, Axsome is addressing growing markets where current treatment options are limited or inadequate. Axsome has a balanced portfolio of clinical development stage as well as research stage products. Axsome Therapeutics aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated products which increase the armamentarium of caregivers and improve the lives of patients. While the focus of the company is on developing its internally derived product candidates, Axsome also evaluates potential in-licensing opportunities to supplement its current portfolio.

Total Funding Amount:

$432M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

New York, New York, United States

Founded Date:

2012-01-01

Contact Email:

info(AT)axsome.com

Founders:

Herriot Tabuteau

Number of Employees:

251-500

Last Funding Date:

2023-06-28

IPO Status:

Public

© 2025 bioDAO.ai